A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.


Updates from The Motley Fool

Latest updates on Arena Pharmaceuticals from Fool.com.  The Fool has written over 400 articles on Arena Pharmaceuticals.
3 Dangerous Stocks

Image source: Shawn Carpenter  via Flickr. While picking winning stocks may seem like the key t...

3 Investing Myths, Debunked!

Photo by StockMonkeys.com / Flickr creative commons Over the long-term, the stock market has crea...



Stock Performance

View Interactive ARNA Charts
Sponsored by

Key Data Points

Primary metrics and data points about Arena Pharmaceuticals.
Current Price: $1.37
Prev Close: $1.40
Open: $1.42
Bid: $1.38
Ask: $1.43
Day's Range: $1.37 - $1.42
52wk Range: $1.30 - $2.16
Volume: 2,196,060
Avg Vol 1,544,520
Market Cap: $332M
P/E (ttm): -3.68
EPS (ttm): ($0.38)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Arena Pharmaceuticals.
CAPS Rating 2 out of 5
 
761 Outperform
70 Underperform
CAPS All Stars
 
103 Outperform
13 Underperform

How do you think Arena Pharmaceuticals will perform against the market?



You pick for Arena Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Jackie Lief, CEO

35% Approve

Based on 7 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Arena Pharmaceuticals.

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers